Navigation Links
Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
Date:10/25/2010

closing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

FORWARD LOOKING STATEMENTS

All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the effort to seek strategic alternatives for the company and our preparations to commercially launch KRYSTEXXA are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, whether an alternative related to the strategic direction of Savient materializes; our ability to commercialize KRYSTEXXA; our reliance on third parties to manufacture, market and distribute KRYSTEXXA; our ability to gain market acceptance for KRYSTEXXA among physicians, patients, health ca
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... The American Association for Homecare (AAHomecare), along with ... , announced today the filing of a lawsuit ... , asking that the scheduled July 1 expansion of the ... be stopped because of serious licensing irregularities. The ... (HHS) Secretary Kathleen Sebelius as the defendant. HHS ...
(Date:6/19/2013)... SUNNYVALE, Calif. , June 19, 2013 ... today announced that The New England Journal of ... a Phase 1b/2 study evaluating the investigational oral Bruton,s ... chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ... patients with relapsed/refractory CLL or SLL, even in patients ...
(Date:6/19/2013)... CHICAGO , June 19, 2013 The Physician-Patient ... reduce alarm fatigue. The need to urgently address ... in its Sentinel Event Alert #50 , "Medical device alarm ... Alert database, between January 2008 and June 2012, there were ... 80 resulted in death (82%) , 13 resulted in ...
Breaking Medicine Technology:AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 2AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 3AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 4AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3
... , ARDEE, Ireland , July 28 Warner Chilcott ... prior to the market opening on Friday, August 6, 2010 . , ... In addition to issuing a press release, the Company will ... at 8:00 AM (Eastern Time) to review the results. To participate ...
... RYE, N.Y. , July 28 Curemark, LLC ... the treatment of neurological diseases, announced that Saint Peter,s University Hospital in ... III clinical trials for CM-AT , Curemark,s autism treatment.   , ... Saint Peter,s is affiliated with ...
Cached Medicine Technology:Warner Chilcott Announces Earnings Release Date and Conference Call for Second Quarter 2010 Financial Results 2Curemark Opens Autism Trials at New Jersey Site 2Curemark Opens Autism Trials at New Jersey Site 3
(Date:6/20/2013)... Minnesota (PRWEB) June 20, 2013 Emotional ... new book about indentifying and confronting tactics used by ... experience with emotional abuse and not being spoken to ... and shamed. She experienced these behaviors and more ... She stayed in the marriage for 13 years because ...
(Date:6/20/2013)... Volume based manufacturing savings have allowed Premier ... of both it's WHEY TOO GOOD Vanilla and WHEY ... Health’s whey protein shake drink mixes are ... to help maintain healthy blood sugar levels, increase energy, ... process. , Ideal for health conscious people interested ...
(Date:6/20/2013)... 20, 2013 Millions of Britons are ... medical conditions because they do not brush their teeth ... Elgydium toothpaste. , Seven million Britons do not clean ... between brushes, latest data from the British Dental Health ... polled by the BDHF also admitted that they forgot ...
(Date:6/20/2013)... (PRWEB) June 20, 2013 Michigan-based natural ... research work by chemist David R Hamilton which revealed ... or planned – resulted in the release of the ... entire body. Oxytocin is known as the ‘cardio protective’ ... in turn, good for heart health. , “Being kind ...
(Date:6/20/2013)... 20, 2013 Startups who need to ... sales or test new markets, and international companies that ... a new sales outsourcing company to help ... , Strategy Sales Partners is a collaboration ... business owners for business owners, Strategy Sales Partners increases ...
Breaking Medicine News(10 mins):Health News:Lisa Kroulik Empowers Women to Recognize Emotional Abuse in Intimate Relationships 2Health News:Premier Natural Health, a Leading Provider of Natural Food Products and Herbal Solutions, Reduces Prices On Its Popular Whey Protein Product 2Health News:Premier Natural Health, a Leading Provider of Natural Food Products and Herbal Solutions, Reduces Prices On Its Popular Whey Protein Product 3Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 2Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 3Health News:Kindness Can Be Good for The Heart Says BioGirl Health Show 2Health News:Kindness Can Be Good for The Heart Says BioGirl Health Show 3Health News:Strategy Sales Partners Launches to Provide Sales Outsourcing Assistance to Businesses 2Health News:Strategy Sales Partners Launches to Provide Sales Outsourcing Assistance to Businesses 3
... in high-expenditure ones, study shows , , TUESDAY, May 27 ... care don,t improve patients, perceptions of the care they ... Medicare beneficiaries. , Per capita spending on Medicare beneficiaries ... health don,t account for this variations, said the ...
... suggests they may help cancer cells resist chemo, radiation ... review of existing research suggests that cancer patients undergoing ... antioxidants. , Although multivitamins may be all right in ... E supplements can spell trouble, said review author Dr. ...
... to describe a chemistry lab. But thanks to a ... is a step closer to being green. , ... Tel Aviv University has discovered a way to use ... of chemical reactions more environmentally-friendly. , Prof. Vigaloks ...
... Ensign,Group, Inc. (Nasdaq: ENSG ), the parent ... care services and assisted living,companies, announced today that ... Annual Spring Investor Conference on May 29, 2008 ... Christensen, CEO, together with Alan,Norman, CFO and Greg ...
... CDD,s software will provide the infrastructure for MRF,s collaborative ... ... BURLINGAME, Calif., May 27 Collaborative Drug,Discovery, Inc. (CDD) announced ... help scientists advance new drug,candidates, has been selected by the ...
... difficile infection following operations for which a "prophylactic" antibiotic ... now than it was just a decade ago, according ... They report their findings in the June 15 issue ... operations that have been associated with severe infections, such ...
Cached Medicine News:Health News:Spending Doesn't Improve Patients' Perception of Care 2Health News:Cancer Patients Should Steer Clear of Antioxidants 2Health News:Cancer Patients Should Steer Clear of Antioxidants 3Health News:1 small step for a lab science, 1 green leap for mankind 2Health News:The Ensign Group to Present at the FBR Capital Markets 12th Annual Spring Investor Conference on May 29th 2Health News:The Ensign Group to Present at the FBR Capital Markets 12th Annual Spring Investor Conference on May 29th 3Health News:Collaborative Drug Discovery and Myelin Repair Foundation Announce Partnership 2Health News:Collaborative Drug Discovery and Myelin Repair Foundation Announce Partnership 3Health News:Collaborative Drug Discovery and Myelin Repair Foundation Announce Partnership 4Health News:The balance shifts 2
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
... Both lenses and frames are designed with ... mind. Our lenses are Schott RS-520 (also called ... shielding glass. These lenses meet standards, as set ... prism correction. ,While our eyewear is protecting ...
... designed with the safety and comfort of the ... (also called SF-6) leaded glass, the industry standard ... as set for optical clarity, visible light transmission, ... is protecting your eyes, it also helps you ...
... are designed with the safety and comfort of ... RS-520 (also called SF-6) leaded glass, the industry ... standards, as set for optical clarity, visible light ... eyewear is protecting your eyes, it also helps ...
Medicine Products: